One of three CD20 X CD3 bispecific antibody candidates striving for a 2023 thumbs up in late-stage diffuse large B-cell lymphoma (DLBCL), Genmab A/S and partner AbbVie Inc.’s epcoritamab is set to be filed in the EU later this year. The firms are also preparing for a US filing in large B-cell lymphoma.
Five Potential Blockbuster Oncology Approvals To Look Out For In 2023
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.
